METHYLERGONOVINE MALEATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Methylergonovine Maleate, and when can generic versions of Methylergonovine Maleate launch?
Methylergonovine Maleate is a drug marketed by Am Regent, Breckenridge, Amneal Pharms, Chartwell Rx, Granules, Rising, Teva Pharms Usa, and Tulex Pharms Inc. and is included in eight NDAs.
The generic ingredient in METHYLERGONOVINE MALEATE is methylergonovine maleate. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the methylergonovine maleate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Methylergonovine Maleate
A generic version of METHYLERGONOVINE MALEATE was approved as methylergonovine maleate by AM REGENT on November 24th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for METHYLERGONOVINE MALEATE?
- What are the global sales for METHYLERGONOVINE MALEATE?
- What is Average Wholesale Price for METHYLERGONOVINE MALEATE?
Summary for METHYLERGONOVINE MALEATE
US Patents: | 0 |
Applicants: | 8 |
NDAs: | 8 |
Finished Product Suppliers / Packagers: | 13 |
Raw Ingredient (Bulk) Api Vendors: | 42 |
Clinical Trials: | 4 |
Patent Applications: | 391 |
Drug Prices: | Drug price information for METHYLERGONOVINE MALEATE |
DailyMed Link: | METHYLERGONOVINE MALEATE at DailyMed |
Recent Clinical Trials for METHYLERGONOVINE MALEATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Johns Hopkins University | Early Phase 1 |
Brigham and Women's Hospital | Phase 4 |
University of California, San Francisco | Phase 4 |
Pharmacology for METHYLERGONOVINE MALEATE
Drug Class | Ergot Derivative |